Assessing the COVID-19 vaccination program during the Omicron variant (B.1.1.529) epidemic in early 2022, Tokyo
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Assessing the COVID-19 vaccination program during the Omicron variant (B.1.1.529) epidemic in early 2022, Tokyo ; volume:23 ; number:1 ; day:31 ; month:10 ; year:2023 ; pages:1-10 ; date:12.2023
BMC infectious diseases ; 23, Heft 1 (31.10.2023), 1-10, 12.2023
- Creator
-
Kayano, Taishi
Nishiura, Hiroshi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12879-023-08748-1
- URN
-
urn:nbn:de:101:1-2024011721103299176554
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kayano, Taishi
- Nishiura, Hiroshi
- SpringerLink (Online service)
Other Objects (12)
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Stability Analysis of B.1.1.529 SARS-Cov-2 Omicron Variant Mathematical Model: The Impacts Of Quarantine And Vaccination
Africans’ response to the January 2023 Omicron variant wave in China: the impact of COVID-19 vaccination status
Effects of COVID-19 vaccination on clinical outcomes in patients hospitalized in Internal Medicine during Omicron variant spreading
Optimal Vaccination in a SIRS Epidemic Model
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Charge Matters: Mutations in Omicron Variant Favor Binding to Cells
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Stability Analysis of B.1.1.529 SARS-Cov-2 Omicron Variant Mathematical Model: The Impacts Of Quarantine And Vaccination
Africans’ response to the January 2023 Omicron variant wave in China: the impact of COVID-19 vaccination status
Effects of COVID-19 vaccination on clinical outcomes in patients hospitalized in Internal Medicine during Omicron variant spreading
Optimal Vaccination in a SIRS Epidemic Model
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Charge Matters: Mutations in Omicron Variant Favor Binding to Cells
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Stability Analysis of B.1.1.529 SARS-Cov-2 Omicron Variant Mathematical Model: The Impacts Of Quarantine And Vaccination
Africans’ response to the January 2023 Omicron variant wave in China: the impact of COVID-19 vaccination status
Effects of COVID-19 vaccination on clinical outcomes in patients hospitalized in Internal Medicine during Omicron variant spreading
Optimal Vaccination in a SIRS Epidemic Model
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Clinical characteristics and booster vaccine effectiveness of the Omicron variant
Charge Matters: Mutations in Omicron Variant Favor Binding to Cells
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2